HL: to what extent does bleomycin pulmonary toxicity affect outcomes?
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
- In patients with Hodgkin's lymphoma (HL), neither bleomycin pulmonary toxicity (BPT) nor bleomycin discontinuation had a meaningful negative effect on survival outcomes.
Why this matters
- Patients receiving bleomycin-containing chemotherapy are at significant risk for morbidity and mortality as a result of BPT.
- Study to investigate incidence, risk factors, and outcomes associated with BPT in 253 patients with HL treated with doxorubicin, bleomycin, vinblastine, and dacarbazine combination (ABVD) therapy.
- Funding: None disclosed.
- 11% overall incidence of BPT.
- 26% of patient...